Lv4
438 积分 2023-01-12 加入
[Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)]
2天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
10天前
已完结
[Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]
16天前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
23天前
已完结
Bispecifics and antibody–drug conjugates: A positive synergy
23天前
已完结
[Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]
24天前
已完结
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)]
24天前
已完结
[Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment (2025 edition)]
24天前
已完结
[Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]
25天前
已完结
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)]
25天前
已完结
皖公网安备34019202002308
